1. Spironolactone reduces sodium reabsorption in the collecting duct by which of the following mechanisms?
A) Directly blocking the Na-K-2Cl cotransporter isoform 2 (NKCC2) on the luminal membrane of thick ascending limb cells
B) Competitively blocking aldosterone binding at the mineralocorticoid receptor (MR) in principal cells, reducing transcription of genes encoding ENaC and the Na/K-ATPase
C) Directly occluding the epithelial sodium channel (ENaC) pore on the luminal surface of collecting duct principal cells
D) Inhibiting carbonic anhydrase in principal cells, reducing the electrochemical gradient that drives sodium entry
E) Blocking the vasopressin type 2 (V2) receptor, preventing aquaporin-2 insertion and reducing the osmotic force that drives sodium cotransport
ANSWER: B
Rationale:
Spironolactone competitively blocks aldosterone at the mineralocorticoid receptor (MR) in collecting duct principal cells. Because aldosterone normally drives transcription of ENaC subunits and the basolateral Na/K-ATPase, MR blockade reduces both, decreasing luminal sodium entry and potassium secretion. The onset is slow (24–72 hours) because it depends on transcriptional downregulation, not direct transporter inhibition — a clinically important distinction from ENaC blockers.
Option A: Option A is incorrect: NKCC2 blockade is the mechanism of loop diuretics such as furosemide, which act in the thick ascending limb, not the collecting duct.
Option C: Option C is incorrect: direct ENaC pore blockade describes amiloride and triamterene, a mechanistically distinct class that acts independently of aldosterone.
Option D: Option D is incorrect: carbonic anhydrase inhibition is the mechanism of acetazolamide, which acts primarily in the proximal convoluted tubule and has no significant effect on collecting duct principal cell sodium transport.
Option E: Option E is incorrect: V2 receptor blockade is the mechanism of vaptans such as tolvaptan; this prevents aquaporin-2 (AQP2) insertion and produces aquaresis, not natriuresis via ENaC.
2. A 54-year-old man with heart failure with reduced ejection fraction (HFrEF) and cirrhotic ascites has been on spironolactone 100 mg daily for eight months. He now reports breast tenderness and bilateral breast enlargement. Which property of spironolactone best explains this adverse effect?
A) Its inhibition of aldosterone synthesis in the adrenal cortex, reducing negative feedback on gonadotropin-releasing hormone and elevating luteinizing hormone levels
B) Its metabolite canrenone acting on renal tubular cells to increase local estrogen production through aromatase upregulation in the collecting duct
C) Its competitive blockade of the mineralocorticoid receptor (MR) in breast tissue, triggering estrogen-receptor cross-activation via downstream cAMP signaling
D) Its binding to androgen and progesterone receptors in addition to the mineralocorticoid receptor (MR), producing endocrine adverse effects due to lack of receptor selectivity
E) Its inhibition of 5-alpha reductase in peripheral tissues, preventing testosterone conversion to dihydrotestosterone and shifting the androgen-to-estrogen balance
ANSWER: D
Rationale:
Spironolactone lacks mineralocorticoid receptor selectivity. The parent compound and its active metabolite canrenone bind to androgen receptors and progesterone receptors, producing gynecomastia, breast tenderness, and menstrual irregularities in a dose-dependent manner. This is the primary tolerability-limiting adverse effect with long-term use, particularly in men, and drove the development of more selective MR antagonists.
Option A: Option A is incorrect: spironolactone does not inhibit aldosterone synthesis; it blocks the receptor for aldosterone. It has no meaningful effect on gonadotropin-releasing hormone (GnRH) or luteinizing hormone (LH) secretion via adrenal synthesis inhibition.
Option B: Option B is incorrect: canrenone acts as an MR antagonist in the kidney; there is no established mechanism by which it induces local aromatase upregulation in collecting duct cells.
Option C: Option C is incorrect: breast tissue does not prominently express mineralocorticoid receptors that signal through cAMP, and cross-activation of estrogen receptors via MR blockade is not the established mechanism of gynecomastia.
Option E: Option E is incorrect: 5-alpha reductase inhibition (as with finasteride or dutasteride) is a separate pharmacological mechanism not shared by spironolactone.
3. Compared with spironolactone, eplerenone is associated with a substantially lower incidence of gynecomastia and menstrual irregularities. What accounts for this difference?
A) Eplerenone has approximately 40-fold lower affinity for androgen and progesterone receptors than spironolactone, making it a far more selective mineralocorticoid receptor (MR) antagonist
B) Eplerenone is a prodrug that requires hepatic activation; the active metabolite does not cross into androgen-receptor-expressing breast tissue due to its hydrophilicity
C) Eplerenone competitively inhibits aromatase in peripheral tissues, reducing local estrogen production and preventing the estrogen excess responsible for spironolactone-induced gynecomastia
D) Eplerenone has a shorter half-life than spironolactone and therefore produces less sustained androgen receptor occupancy over a 24-hour dosing interval
E) Eplerenone acts exclusively on the basolateral Na/K-ATPase rather than on intracellular steroid hormone receptors, avoiding cross-reactivity with sex hormone receptors entirely
ANSWER: A
Rationale:
Eplerenone was developed specifically to address spironolactone's lack of receptor selectivity. Its chemical structure confers approximately 40-fold lower affinity for androgen and progesterone receptors compared with spironolactone, with preserved high affinity for the mineralocorticoid receptor (MR). This selectivity substantially reduces the incidence of gynecomastia, breast tenderness, and menstrual irregularities, improving tolerability in long-term use. Eplerenone is metabolized primarily by CYP3A4, creating significant drug interactions with strong CYP3A4 inhibitors and inducers.
Option B: Option B is incorrect: eplerenone is not a prodrug; it is pharmacologically active as administered. Triamterene, not eplerenone, undergoes hepatic activation to an active metabolite.
Option C: Option C is incorrect: eplerenone does not inhibit aromatase; aromatase inhibitors (anastrozole, letrozole) are a separate drug class used in oncology and endocrinology.
Option D: Option D is incorrect: the basis for eplerenone's better tolerability is receptor selectivity, not half-life difference. Half-life differences between steroidal MR antagonists do not explain the gynecomastia differential.
Option E: Option E is incorrect: like spironolactone, eplerenone acts on intracellular steroid hormone receptors, not on the basolateral Na/K-ATPase directly; its advantage is selectivity within the nuclear receptor family, not a fundamentally different mechanism class.
4. Finerenone differs from spironolactone and eplerenone in both chemical structure and clinical evidence base. Which statement most accurately characterizes finerenone?
A) Finerenone is a loop diuretic derivative with additional mineralocorticoid receptor (MR) antagonist activity, combining natriuresis with aldosterone blockade in a single molecule
B) Finerenone selectively inhibits aldosterone synthase (CYP11B2) in the adrenal cortex, reducing circulating aldosterone levels rather than blocking the receptor
C) Finerenone is a nonsteroidal MR antagonist with greater MR selectivity and lower hyperkalemia incidence than steroidal agents, with outcomes trials demonstrating benefit in diabetic chronic kidney disease (CKD)
D) Finerenone is a steroidal MR antagonist identical in mechanism to eplerenone but with higher renal tissue distribution, producing more effective natriuresis in patients with advanced CKD
E) Finerenone is approved exclusively for primary hyperaldosteronism and lacks evidence in heart failure or CKD populations
ANSWER: C
Rationale:
Finerenone is a nonsteroidal MR antagonist with a distinct chemical scaffold that provides greater MR selectivity than both spironolactone and eplerenone. Its tissue distribution profile shows higher relative cardiac and lower renal receptor occupancy compared with steroidal MR antagonists, which translates into reduced hyperkalemia incidence at equivalent MR-blocking doses. The FIDELIO-DKD trial demonstrated that finerenone reduced the composite of kidney failure, sustained eGFR decline, and renal death in patients with type 2 diabetes and CKD, and the FIGARO-DKD trial demonstrated cardiovascular benefit in the same population — establishing finerenone as a disease-modifying agent in diabetic CKD.
Option A: Option A is incorrect: finerenone is not a loop diuretic derivative; it belongs to a distinct nonsteroidal MR antagonist class with no NKCC2 inhibitory activity.
Option B: Option B is incorrect: finerenone does not inhibit aldosterone synthase (CYP11B2); aldosterone synthase inhibitors are an investigational class distinct from MR antagonists.
Option D: Option D is incorrect: finerenone is nonsteroidal, not a steroidal agent like eplerenone, and its lower renal distribution (not higher) contributes to reduced hyperkalemia risk.
Option E: Option E is incorrect: finerenone has substantial outcomes evidence in diabetic CKD across the FIDELIO-DKD and FIGARO-DKD trials; primary hyperaldosteronism is an indication for spironolactone, not finerenone's primary evidence base.
5. A hospitalized patient with decompensated heart failure and stage 3b chronic kidney disease (CKD) has a serum potassium of 5.3 mEq/L and an eGFR of 26 mL/min/1.73 m². She is currently on lisinopril, carvedilol, and furosemide. The team considers adding spironolactone. Which of the following correctly identifies the primary contraindication to MR antagonist initiation in this patient?
A) Concurrent furosemide use is an absolute contraindication to MR antagonist therapy because loop diuretics and potassium-sparing diuretics act at opposing tubular sites and cancel each other's natriuretic effects
B) Carvedilol's beta-1 blockade suppresses renin release, rendering aldosterone levels negligible and making MR antagonist therapy pharmacologically futile in beta-blocked patients
C) Lisinopril and spironolactone share the same receptor superfamily and compete for the same binding site, producing pharmacodynamic antagonism that nullifies the benefit of either agent
D) Spironolactone should not be added because the combination of an ACE inhibitor with an MR antagonist is universally contraindicated by FDA labeling regardless of renal function or potassium level
E) MR antagonists are generally contraindicated when eGFR falls below 30 mL/min/1.73 m² or baseline serum potassium exceeds 5.0 mEq/L due to the substantial risk of life-threatening hyperkalemia
ANSWER: E
Rationale:
MR antagonists impair potassium excretion by reducing aldosterone-driven potassium secretion via ROMK in the collecting duct. When eGFR falls below 30 mL/min/1.73 m², the kidney's capacity to excrete potassium is already substantially reduced, and adding an MR antagonist creates a high risk of severe hyperkalemia. A baseline potassium above 5.0 mEq/L is itself a contraindication regardless of eGFR. This patient has both: eGFR of 26 and potassium of 5.3 — making spironolactone initiation contraindicated. Concurrent ACE inhibitor use (lisinopril) further amplifies the risk by also reducing angiotensin II-driven aldosterone release, adding a second potassium-retaining mechanism.
Option A: Option A is incorrect: furosemide and spironolactone are routinely co-prescribed in heart failure and cirrhosis; they do not cancel each other's effects and are often combined specifically to balance potassium losses from loop diuretics with potassium retention from the MR antagonist.
Option B: Option B is incorrect: carvedilol does reduce renin release via beta-1 blockade, modestly lowering aldosterone, but MR antagonist therapy retains clinical benefit in beta-blocked patients and is standard of care in HFrEF regardless of beta-blocker use.
Option C: Option C is incorrect: ACE inhibitors (lisinopril) and MR antagonists (spironolactone) act through entirely different mechanisms and receptor systems; they do not compete for shared binding sites.
Option D: Option D is incorrect: the FDA does not universally prohibit ACE inhibitor and MR antagonist co-administration; dual RAAS blockade with this combination is a recognized strategy in HFrEF and cirrhosis, but requires careful potassium and renal monitoring.
6. Amiloride produces potassium retention and mild natriuresis by which mechanism, and how does this differ from spironolactone?
A) Amiloride competitively blocks aldosterone at the mineralocorticoid receptor (MR), reducing ENaC transcription with a 24–72 hour onset; spironolactone directly occludes the ENaC pore for immediate sodium blockade
B) Amiloride directly blocks the epithelial sodium channel (ENaC) pore on the luminal surface of collecting duct principal cells independently of aldosterone, producing an immediate effect regardless of aldosterone status
C) Amiloride inhibits the renal outer medullary potassium channel (ROMK) directly, preventing potassium secretion without affecting sodium reabsorption, while spironolactone reduces potassium secretion indirectly through MR blockade
D) Amiloride blocks the basolateral Na/K-ATPase in collecting duct principal cells, reducing intracellular sodium and indirectly diminishing the electrochemical gradient driving ENaC-mediated luminal entry
E) Amiloride activates atrial natriuretic peptide (ANP) receptors in the collecting duct, which phosphorylate and inactivate ENaC subunits through a cGMP-dependent pathway independent of aldosterone signaling
ANSWER: B
Rationale:
Amiloride blocks the epithelial sodium channel (ENaC) directly at the luminal surface of collecting duct principal cells, acting independently of aldosterone. Because ENaC-mediated sodium entry creates the lumen-negative electrochemical potential that drives potassium secretion via ROMK, blocking ENaC simultaneously reduces sodium absorption and potassium secretion. The effect is immediate — it does not require transcriptional changes — distinguishing amiloride from MR antagonists such as spironolactone, which require 24–72 hours to reduce ENaC expression through downregulation of aldosterone-dependent gene transcription. Amiloride is also effective regardless of circulating aldosterone levels, making it useful even in states of low aldosterone where spironolactone would have reduced efficacy.
Option A: Option A is incorrect: the mechanisms are reversed. Spironolactone (not amiloride) blocks the MR with slow onset, while amiloride (not spironolactone) directly occludes the ENaC pore with immediate effect.
Option C: Option C is incorrect: amiloride does not directly block ROMK; potassium retention results indirectly from reduced lumen-negative potential after ENaC blockade, not from direct ROMK inhibition.
Option D: Option D is incorrect: amiloride's site of action is the luminal ENaC, not the basolateral Na/K-ATPase; Na/K-ATPase blockade is the mechanism of cardiac glycosides such as digoxin.
Option E: Option E is incorrect: amiloride does not activate ANP receptors or operate through a cGMP-dependent mechanism; ANP's renal effects include natriuresis and reduced aldosterone secretion through separate receptor systems.
7. A 38-year-old man with bipolar disorder has been on lithium for five years and now presents with polyuria of 4–6 liters per day and a urine osmolality of 145 mOsm/kg that fails to concentrate after water deprivation. His serum lithium level is therapeutic. He requires a diuretic to manage edema from a concurrent medication. Which agent is most appropriate, and why?
A) Furosemide, because loop diuretics reduce lithium reabsorption in the thick ascending limb, lowering serum lithium levels and simultaneously treating the nephrogenic diabetes insipidus (NDI)
B) Hydrochlorothiazide, because thiazides paradoxically reduce urine output in nephrogenic diabetes insipidus (NDI) by inducing mild volume contraction that upregulates proximal lithium and water reabsorption
C) Spironolactone, because mineralocorticoid receptor (MR) antagonism in the collecting duct reduces the aldosterone-driven ENaC upregulation that mediates lithium entry into principal cells and causes aquaporin-2 (AQP2) downregulation
D) Amiloride, because it blocks the epithelial sodium channel (ENaC) through which lithium enters collecting duct principal cells, reducing intracellular lithium accumulation and attenuating aquaporin-2 (AQP2) downregulation
E) Tolvaptan, because V2 receptor blockade prevents aquaporin-2 insertion and directly restores urinary concentrating ability in lithium-induced nephrogenic diabetes insipidus (NDI)
ANSWER: D
Rationale:
Lithium enters collecting duct principal cells via ENaC on the luminal surface — the same channel that mediates sodium entry. Once inside the cell, lithium downregulates aquaporin-2 (AQP2) expression, impairing urinary concentrating ability and producing nephrogenic diabetes insipidus (NDI). Amiloride blocks ENaC directly, reducing lithium entry into principal cells, preserving AQP2 expression, and improving urinary concentration. It is the preferred agent both for treating lithium-induced NDI and for providing diuresis in lithium-treated patients because it does not upregulate proximal sodium-lithium cotransport — which would raise serum lithium levels — unlike loop diuretics and thiazides.
Option A: Option A is incorrect: furosemide promotes proximal tubular sodium (and lithium) reabsorption by reducing volume, which can raise serum lithium to toxic levels; it is not the preferred diuretic in lithium-treated patients and does not treat lithium-induced NDI.
Option B: Option B is incorrect: while thiazides can reduce urine output in NDI via volume-contraction-driven proximal reabsorption, they also promote proximal lithium reabsorption and can increase serum lithium to toxic levels, making them hazardous without careful monitoring; amiloride is preferred.
Option C: Option C is incorrect: spironolactone blocks MR and reduces aldosterone-driven ENaC transcription, but ENaC-mediated lithium entry occurs through the channel regardless of aldosterone status, and MR antagonism is not the established treatment for lithium-induced NDI.
Option E: Option E is incorrect: tolvaptan blocks V2 receptors and prevents AQP2 insertion, which would worsen NDI rather than treat it by further reducing AQP2-mediated water reabsorption.
8. A patient with Child-Pugh class B cirrhosis requires an ENaC blocker to counteract thiazide-induced hypokalemia. Why is amiloride preferred over triamterene in this setting?
A) Triamterene is a prodrug that requires hepatic activation to its active hydroxytriamterene metabolite; hepatic dysfunction significantly impairs this conversion, reducing efficacy, whereas amiloride is pharmacologically active as administered
B) Triamterene is a potent CYP3A4 inhibitor, and patients with cirrhosis already have elevated exposure to hepatically metabolized drugs, creating a dangerous pharmacokinetic interaction that does not affect amiloride
C) Triamterene undergoes extensive renal elimination exclusively as unchanged drug, and the renal hypoperfusion common in advanced cirrhosis causes severe triamterene accumulation before the drug can exert any ENaC blockade
D) Triamterene activates mineralocorticoid receptors (MR) in cirrhotic patients due to altered receptor expression, paradoxically promoting sodium and water retention rather than the intended natriuresis
E) Triamterene requires co-administration with aldosterone to activate ENaC blockade, and the low aldosterone state characteristic of Child-Pugh class B cirrhosis renders it pharmacologically inert in this population
ANSWER: A
Rationale:
Triamterene is a prodrug that must undergo hepatic biotransformation to its active metabolite, hydroxytriamterene sulfate, to exert ENaC-blocking activity. In patients with significant hepatic dysfunction — as in Child-Pugh class B or C cirrhosis — this hepatic activation is impaired, reducing the generation of active drug and diminishing efficacy. Additionally, triamterene and its metabolites are renally eliminated; renal impairment, which frequently accompanies advanced cirrhosis, leads to metabolite accumulation and heightened hyperkalemia risk. Amiloride is pharmacologically active as administered, has reliable oral bioavailability, and does not depend on hepatic activation, making it the preferred ENaC blocker in cirrhotic patients.
Option B: Option B is incorrect: triamterene is not a CYP3A4 inhibitor; its pharmacokinetic interaction concern in cirrhosis relates to impaired prodrug activation, not CYP3A4 inhibition. Eplerenone (not triamterene) has important CYP3A4-mediated drug interactions.
Option C: Option C is incorrect: while triamterene is renally eliminated (which does create accumulation risk in CKD and hepatorenal syndrome), the primary reason to avoid triamterene in cirrhosis is its dependence on hepatic activation as a prodrug, not solely renal accumulation.
Option D: Option D is incorrect: triamterene does not activate MR; it blocks ENaC directly and independently of the MR.
Option E: Option E is incorrect: triamterene blocks ENaC independently of aldosterone status; ENaC direct-blockers do not require aldosterone to be present for their effect, which is precisely what distinguishes them from MR antagonists.
9. Acetazolamide produces its diuretic and acid-base effects through which primary mechanism?
A) Blocking the Na-Cl cotransporter (NCC) in the distal convoluted tubule (DCT), preventing sodium and chloride reabsorption and producing a mild metabolic alkalosis from chloride wasting
B) Competitively inhibiting the sodium-hydrogen exchanger isoform 3 (NHE3) directly at its luminal binding site in the proximal convoluted tubule (PCT), reducing bicarbonate reabsorption without affecting carbonic anhydrase activity
C) Inhibiting luminal carbonic anhydrase IV (CA IV) and cytoplasmic carbonic anhydrase II (CA II) in the proximal convoluted tubule (PCT), impairing NHE3-mediated sodium-bicarbonate reabsorption and causing urinary wasting of sodium bicarbonate with predictable metabolic acidosis
D) Blocking the vacuolar H+-ATPase (proton pump) in intercalated cells of the collecting duct, reducing hydrogen ion secretion and causing systemic bicarbonate retention and metabolic alkalosis
E) Inhibiting the basolateral sodium-bicarbonate cotransporter (NBC1) in proximal tubule cells, trapping bicarbonate intracellularly and preventing its return to the peritubular capillaries
ANSWER: C
Rationale:
In the proximal convoluted tubule (PCT), bicarbonate reabsorption depends on a coupled process: luminal carbonic anhydrase IV (CA IV) dehydrates carbonic acid to CO₂ and water, allowing CO₂ to diffuse across the apical membrane; intracellular carbonic anhydrase II (CA II) then rehydrates CO₂ to regenerate H⁺ for the NHE3 sodium-hydrogen exchanger. When acetazolamide inhibits both CA IV and CA II, this coupled process is broken, NHE3-mediated sodium reabsorption is impaired, and sodium bicarbonate (NaHCO₃) is wasted in the urine. The resulting urinary alkalinization and systemic metabolic acidosis are predictable, dose-dependent, and constitute the pharmacological basis for all of acetazolamide's clinical uses.
Option A: Option A is incorrect: NCC blockade in the DCT is the mechanism of thiazide and thiazide-like diuretics such as hydrochlorothiazide and metolazone; these agents cause metabolic alkalosis (from kaliuresis and volume contraction), not metabolic acidosis.
Option B: Option B is incorrect: acetazolamide does not directly inhibit NHE3 at its luminal binding site; its action is on carbonic anhydrase enzymes, and NHE3 impairment is downstream of CA inhibition rather than direct NHE3 blockade.
Option D: Option D is incorrect: the vacuolar H+-ATPase in intercalated cells of the collecting duct mediates urinary acidification; blocking it would reduce acid secretion and cause alkalosis, the opposite of acetazolamide's effect.
Option E: Option E is incorrect: while the basolateral sodium-bicarbonate cotransporter (NBC1) participates in proximal tubular bicarbonate handling, acetazolamide does not block NBC1; it targets carbonic anhydrase enzymes on the luminal and cytoplasmic faces of proximal tubule cells.
10. A mountaineer planning ascent to 4,500 meters is prescribed acetazolamide for altitude sickness prophylaxis. Which of the following best explains the mechanism by which acetazolamide prevents altitude sickness symptoms?
A) Acetazolamide induces peripheral vasoconstriction by inhibiting endothelial carbonic anhydrase, raising mean arterial pressure and improving cerebral perfusion pressure at altitude
B) Acetazolamide reduces cerebrospinal fluid (CSF) production by inhibiting choroid plexus carbonic anhydrase, directly lowering intracranial pressure and preventing high-altitude cerebral edema
C) Acetazolamide promotes renal bicarbonate reabsorption at altitude, correcting the respiratory alkalosis through enhanced buffering rather than through increased ventilation
D) Acetazolamide stimulates erythropoietin (EPO) release by inhibiting renal carbonic anhydrase, accelerating red blood cell production and improving oxygen-carrying capacity within 24–48 hours of ascent
E) Acetazolamide induces metabolic acidosis by causing urinary bicarbonate wasting, which counteracts hypoxia-driven respiratory alkalosis and restores the acid stimulus to peripheral chemoreceptors, maintaining ventilatory drive at altitude
ANSWER: E
Rationale:
At high altitude, hypoxia drives hyperventilation, which lowers PaCO₂ and raises arterial pH — producing respiratory alkalosis. This alkalosis blunts the activity of peripheral chemoreceptors, reducing the ventilatory drive that is needed to maintain adequate oxygenation at altitude and contributing to altitude sickness symptoms including headache, nausea, and sleep-disordered breathing. Acetazolamide inhibits renal carbonic anhydrase, causing urinary wasting of bicarbonate (bicarbonaturia) and producing a compensatory metabolic acidosis. This metabolic acidosis counteracts the respiratory alkalosis, restores the pH-sensitive stimulation of peripheral chemoreceptors, and sustains the hypoxic ventilatory response. The net effect is improved ventilation and oxygenation at altitude. Acetazolamide is sulfonamide-derived; patients with confirmed sulfonamide allergy should receive dexamethasone instead.
Option A: Option A is incorrect: acetazolamide does not induce peripheral vasoconstriction via endothelial CA inhibition; it actually produces some vasodilation through CO₂-mediated effects, and its altitude benefit is ventilatory, not hemodynamic.
Option B: Option B is incorrect: while acetazolamide does reduce CSF production via choroid plexus CA inhibition (a basis for its use in pseudotumor cerebri), this mechanism is not the primary explanation for its altitude sickness prophylaxis benefit, which centers on restoring ventilatory drive.
Option C: Option C is incorrect: acetazolamide promotes bicarbonate wasting (bicarbonaturia), not reabsorption; it lowers serum bicarbonate and worsens metabolic alkalosis management by correcting alkalosis, not by enhancing bicarbonate retention.
Option D: Option D is incorrect: acetazolamide does not stimulate EPO release or accelerate erythropoiesis; EPO production is regulated by hypoxia-inducible factor (HIF), not by carbonic anhydrase activity.
11. A patient with decompensated heart failure and severe volume overload has been receiving high-dose IV furosemide for three days. His current arterial blood gas shows pH 7.51, PaCO₂ 48 mmHg, and serum bicarbonate 38 mEq/L, consistent with metabolic alkalosis. He cannot receive IV saline because of his volume-overloaded state. Which agent is most appropriate to correct this alkalosis?
A) Potassium chloride (KCl) infusion alone, because metabolic alkalosis in diuretic-treated patients is driven exclusively by hypokalemia, and potassium repletion without any additional agent will fully normalize serum bicarbonate within 24 hours
B) Acetazolamide, because it inhibits proximal tubular carbonic anhydrase and forces urinary bicarbonate wasting (bicarbonaturia) without requiring sodium loading, correcting metabolic alkalosis safely in volume-overloaded patients
C) Sodium bicarbonate infusion, because metabolic alkalosis from loop diuretic therapy represents a bicarbonate deficit that requires direct bicarbonate supplementation to restore normal serum levels
D) Spironolactone, because mineralocorticoid receptor (MR) antagonism blocks the aldosterone-driven bicarbonate reabsorption that generates and maintains metabolic alkalosis in loop diuretic-treated patients
E) Stopping furosemide permanently, because metabolic alkalosis in this setting is self-correcting once the causative loop diuretic is withdrawn, without any additional pharmacological intervention required
ANSWER: B
Rationale:
Loop and thiazide diuretics cause metabolic alkalosis through multiple mechanisms: volume contraction raises serum bicarbonate by concentration, hypokalemia promotes intracellular hydrogen ion shifts that raise plasma bicarbonate, and secondary hyperaldosteronism drives proton secretion by intercalated cells. Normally this is corrected with saline (to replace chloride and reverse contraction) and potassium repletion. In volume-overloaded heart failure patients who cannot safely receive saline, acetazolamide provides an alternative: by inhibiting proximal tubular carbonic anhydrase, it forces urinary bicarbonate wasting without adding sodium to the system. The resulting bicarbonaturia lowers serum bicarbonate without worsening volume overload. The ADVOR trial subsequently validated the use of acetazolamide in this clinical context, demonstrating improved decongestion when added to IV loop diuretics.
Option A: Option A is incorrect: while potassium repletion is a necessary component of managing diuretic-induced metabolic alkalosis, it does not fully correct serum bicarbonate when contraction alkalosis is the dominant mechanism; acetazolamide is needed to address the bicarbonate directly in the sodium-restricted setting.
Option C: Option C is incorrect: sodium bicarbonate infusion would worsen rather than correct metabolic alkalosis by directly adding bicarbonate; it would also worsen volume overload.
Option D: Option D is incorrect: spironolactone blocks MR and reduces aldosterone-driven proton secretion, which can modestly reduce alkalosis generation, but it does not directly force bicarbonaturia and is not the standard pharmacological correction for established metabolic alkalosis in this setting.
Option E: Option E is incorrect: while diuretic dose reduction may be appropriate clinically, metabolic alkalosis in volume-overloaded patients is not reliably self-correcting after cessation alone, and the clinical priority of continued decongestion must be balanced against the alkalosis — acetazolamide allows continuation of loop diuresis while addressing the alkalosis simultaneously.
12. Mannitol produces diuresis through which mechanism that distinguishes it from all other diuretic classes?
A) Mannitol inhibits the proximal tubular sodium-glucose cotransporter 2 (SGLT2), blocking glucose-coupled sodium reabsorption and obligating osmotic water loss in the proximal tubule
B) Mannitol activates renal prostaglandin synthesis, producing afferent arteriolar dilation and increasing glomerular filtration rate (GFR) to drive osmotic diuresis through increased filtration load
C) Mannitol competitively inhibits aquaporin-1 (AQP1) water channels in the proximal convoluted tubule and descending limb, blocking transcellular water reabsorption and forcing water retention in the tubular lumen
D) Mannitol is freely filtered at the glomerulus and neither reabsorbed nor secreted by the renal tubule, creating an osmotic force in the tubular lumen that holds water and opposes reabsorption throughout the nephron
E) Mannitol blocks the urea transporter (UT-A1) in the inner medullary collecting duct, reducing the hypertonicity of the medullary interstitium and diminishing the osmotic driving force for tubular water reabsorption
ANSWER: D
Rationale:
Mannitol is a six-carbon sugar alcohol that is freely filtered at the glomerulus but — unlike glucose — is neither reabsorbed by tubular transporters nor secreted into the tubular lumen. Its persistent presence in the tubular fluid exerts an osmotic force that retains water within the lumen, opposing the normal transcellular reabsorption driven by tubular hypertonicity and active sodium transport. In the proximal convoluted tubule (PCT), where the majority of water reabsorption is osmotically coupled to solute transport, mannitol's osmotic effect is greatest. Increased tubular flow also dilutes other solutes and reduces their driving force for reabsorption. The net result is increased urine output with modest electrolyte losses. This mechanism — purely osmotic, requiring no specific transporter interaction — is unique among diuretic classes.
Option A: Option A is incorrect: SGLT2 inhibition is the mechanism of gliflozin agents such as empagliflozin and dapagliflozin, which act at the apical SGLT2 transporter in the PCT; mannitol has no SGLT2 activity.
Option B: Option B is incorrect: mannitol does not activate renal prostaglandin synthesis or increase GFR through afferent arteriolar dilation; its diuretic effect occurs downstream of filtration through the osmotic mechanism described.
Option C: Option C is incorrect: mannitol does not block aquaporin-1 (AQP1); no approved diuretic acts by direct aquaporin channel blockade. Vaptans block V2 receptor-mediated AQP2 insertion, a different aquaporin in a different nephron segment.
Option E: Option E is incorrect: blocking urea transporters would affect medullary tonicity, but mannitol does not interact with UT-A1; its mechanism is purely the luminal osmotic effect of an unabsorbable solute.
13. A 28-year-old man arrives by emergency transport after a high-speed motor vehicle collision. CT scan reveals diffuse cerebral edema with midline shift. His GCS (Glasgow Coma Scale) is 8. IV mannitol is ordered. By which mechanisms does mannitol acutely reduce intracranial pressure (ICP)?
A) Mannitol creates an osmotic gradient that draws water from brain parenchyma into plasma, and reduces blood viscosity to improve cerebral blood flow, triggering compensatory autoregulatory vasoconstriction that further reduces cerebral blood volume
B) Mannitol inhibits vasopressin release from the posterior pituitary, reducing aquaporin-mediated water entry into brain cells and producing rapid cerebral dehydration through antidiuretic hormone (ADH) suppression
C) Mannitol crosses the blood-brain barrier to act directly on cerebral astrocytes, activating chloride-bicarbonate exchangers that pump intracellular water out of cells through an active transport mechanism
D) Mannitol reduces ICP by inhibiting choroid plexus carbonic anhydrase, reducing cerebrospinal fluid (CSF) production and lowering the CSF compartment's contribution to total intracranial volume
E) Mannitol acts on cerebral venous endothelium to promote aquaporin-4 (AQP4) internalization, reducing astrocyte end-foot water permeability and limiting the entry of edema fluid into the perivascular space
ANSWER: A
Rationale:
Mannitol reduces ICP through two complementary mechanisms. First and most rapidly: the osmotic gradient created by IV mannitol (serum osmolality rises above brain interstitial osmolality) draws water from brain parenchyma across the blood-brain barrier into the intravascular space, reducing brain water content. This effect begins within 15–30 minutes and is the dominant acute mechanism. Second: by reducing blood viscosity through hemodilution, mannitol transiently improves cerebral blood flow; intact cerebrovascular autoregulation responds by vasoconstricting cerebral arterioles, reducing cerebral blood volume and ICP further. Standard dosing is 0.25–1 g/kg IV over 20–30 minutes, titrated to a serum osmolality target of 310–320 mOsm/kg.
Option B: Option B is incorrect: mannitol does not inhibit vasopressin (ADH) release; it is an osmotic agent that acts peripherally in the bloodstream and does not affect the hypothalamic-pituitary axis to suppress ADH secretion.
Option C: Option C is incorrect: mannitol does not cross the intact blood-brain barrier and does not act directly on cerebral astrocytes; its mechanism is entirely intravascular and osmotic, drawing water out of the brain rather than pumping it out from within cells.
Option D: Option D is incorrect: choroid plexus carbonic anhydrase inhibition is the mechanism of acetazolamide, which reduces CSF production; mannitol has no carbonic anhydrase inhibitory activity.
Option E: Option E is incorrect: mannitol does not target aquaporin-4 (AQP4) internalization in cerebral astrocytes; AQP4 modulation is under investigation as a therapeutic target but is not the mechanism of mannitol's established ICP-reducing effect.
14. A 67-year-old man with anuric acute kidney injury (AKI) develops intracranial hypertension following traumatic brain injury. The neurosurgical team requests IV mannitol for ICP management. Why is mannitol contraindicated in this patient despite the urgent neurological indication?
A) Anuric patients have elevated serum urea that competes with mannitol for tubular secretion, blocking mannitol's elimination and causing an unpredictable extension of its half-life without increasing its pharmacological effect
B) Anuria prevents glomerular filtration of mannitol, so the drug accumulates in the bloodstream and is instead metabolized to toxic aldehydes that cross the blood-brain barrier and worsen cerebral edema
C) In anuric patients, mannitol cannot be excreted and accumulates in plasma, persistently expanding intravascular volume, raising serum osmolality, and potentially precipitating pulmonary edema without achieving the desired ICP reduction
D) Anuria indicates complete glomerular shutdown; mannitol requires filtration to exert its osmotic diuretic effect, so the drug has no mechanism of action and is simply pharmacologically inert in the anuric state
E) Mannitol is highly protein-bound in the hyperproteinemic state that accompanies anuric AKI, reducing its free plasma concentration below the threshold needed to create an effective osmotic gradient
ANSWER: C
Rationale:
Mannitol's entire therapeutic action depends on being filtered at the glomerulus, retained in the tubular lumen, and ultimately excreted in the urine. In anuric patients, glomerular filtration is absent or negligible, so mannitol cannot be excreted. Instead, it accumulates in the intravascular space, where it draws water from body compartments (including tissues) into the bloodstream through its osmotic effect — expanding intravascular volume, raising plasma osmolality to potentially dangerous levels, and risking acute pulmonary edema from the volume expansion that precedes any beneficial ICP effect. The hypertonicity itself can also paradoxically worsen cerebral edema once the osmotic gradient equilibrates. In anuric patients, hypertonic saline is the preferred alternative for ICP management.
Option A: Option A is incorrect: urea is not a tubular secretion competitor with mannitol; mannitol is neither secreted nor reabsorbed, and its elimination depends on glomerular filtration. Urea does not compete for the same tubular transport systems as mannitol.
Option B: Option B is incorrect: mannitol is not metabolized to toxic aldehydes; it is poorly metabolized in humans and relies on renal excretion. It does not cross the intact blood-brain barrier in meaningful amounts.
Option D: Option D is incorrect: while it is true that mannitol's diuretic effect is absent in anuria, the danger is not merely pharmacological inertness — mannitol continues to exert intravascular osmotic effects and causes volume expansion and hypertonicity even without diuresis.
Option E: Option E is incorrect: mannitol is not significantly protein-bound; it distributes freely in the extracellular fluid and is not subject to protein-binding limitations on its pharmacological activity.
15. Tolvaptan raises serum sodium in patients with hyponatremia by which mechanism?
A) Tolvaptan competitively inhibits aldosterone at the mineralocorticoid receptor (MR) in collecting duct principal cells, reducing ENaC-mediated sodium loss and restoring serum sodium by preventing further dilutional hyponatremia
B) Tolvaptan inhibits the Na-K-2Cl cotransporter isoform 2 (NKCC2) in the thick ascending limb, generating a dilute urine that frees retained water to be excreted, raising serum sodium concentrations over 24–48 hours
C) Tolvaptan activates vasopressin type 2 (V2) receptors in collecting duct principal cells, amplifying cAMP production and driving maximal aquaporin-2 (AQP2) insertion to generate the most concentrated urine possible
D) Tolvaptan inhibits carbonic anhydrase in collecting duct intercalated cells, reducing bicarbonate-mediated water cotransport and promoting electrolyte-free water excretion through a pH-dependent mechanism
E) Tolvaptan blocks vasopressin type 2 (V2) receptors in collecting duct principal cells, preventing the cAMP-mediated insertion of aquaporin-2 (AQP2) water channels and allowing excretion of electrolyte-free water (aquaresis) that raises serum sodium without depleting total body sodium
ANSWER: E
Rationale:
Vasopressin (antidiuretic hormone, ADH) normally binds V2 receptors on collecting duct principal cells, activating adenylyl cyclase to produce cyclic AMP (cAMP), which triggers protein kinase A-mediated trafficking of aquaporin-2 (AQP2)-containing vesicles to the apical membrane. This AQP2 insertion allows luminal water to move down the osmotic gradient into the hypertonic medullary interstitium, concentrating the urine. Tolvaptan competitively blocks V2 receptors, preventing cAMP generation and AQP2 insertion. The result is excretion of electrolyte-free water — aquaresis — without sodium loss, which raises serum sodium concentration without depleting total body sodium stores. This is the defining pharmacological distinction that makes vaptans appropriate for hyponatremia in states of normal or elevated total body sodium (SIADH, heart failure, cirrhosis).
Option A: Option A is incorrect: MR antagonism describes the mechanism of spironolactone, eplerenone, and finerenone, which preserve potassium but do not produce aquaresis or correct hyponatremia by removing free water without sodium.
Option B: Option B is incorrect: NKCC2 inhibition is the mechanism of loop diuretics such as furosemide; these drugs can worsen hyponatremia in some settings by producing more electrolyte loss than free water loss.
Option C: Option C is incorrect: this describes the action of vasopressin itself — tolvaptan antagonizes, not activates, V2 receptors; stimulating V2 would produce urine concentration and worsen hyponatremia by retaining free water.
Option D: Option D is incorrect: tolvaptan has no carbonic anhydrase inhibitory activity; this describes the mechanism of acetazolamide, which acts in the proximal convoluted tubule and has no meaningful AQP2-related effect.
16. A patient with SIADH (syndrome of inappropriate antidiuretic hormone secretion) has a serum sodium of 122 mEq/L despite fluid restriction. The team debates between tolvaptan and furosemide for additional management. Which statement correctly contrasts these agents in the context of hyponatremia management?
A) Furosemide is preferred over tolvaptan in SIADH because loop diuretics selectively remove the excess water retained by inappropriate ADH activity without affecting sodium balance, while tolvaptan raises serum sodium by simultaneously increasing sodium excretion and water excretion
B) Tolvaptan produces aquaresis — excretion of electrolyte-free water without sodium loss — which raises serum sodium without depleting total body sodium; furosemide produces natriuresis, removing both sodium and water, which can worsen or fail to correct hyponatremia depending on the urine-to-plasma electrolyte ratio
C) Tolvaptan and furosemide both work by blocking vasopressin activity in the collecting duct, but tolvaptan acts at the receptor level while furosemide acts downstream by preventing AQP2 phosphorylation, making them pharmacodynamically equivalent for hyponatremia correction
D) Furosemide corrects SIADH hyponatremia more reliably than tolvaptan because the natriuresis it produces raises serum osmolality directly by concentrating remaining body fluids, a more potent mechanism than electrolyte-free water removal
E) Tolvaptan is appropriate for hypovolemic hyponatremia caused by total body sodium depletion, where its selective water removal allows sodium conservation while correcting the free water excess that characterizes this condition
ANSWER: B
Rationale:
The central distinction is aquaresis versus natriuresis. Vaptans such as tolvaptan block V2 receptors, preventing AQP2 insertion in the collecting duct and generating electrolyte-free water excretion. Because sodium is not lost in this urine, serum sodium rises without any reduction in total body sodium — the ideal pharmacological action in SIADH, where the problem is excess free water retention, not sodium depletion. Loop diuretics such as furosemide produce natriuresis: the excreted urine contains both sodium and water. In SIADH, furosemide may worsen hyponatremia if the urine sodium concentration exceeds plasma sodium, or provide insufficient correction; it is not the preferred agent for SIADH-related hyponatremia.
Option A: Option A is incorrect: furosemide does not selectively remove excess water; it removes sodium and water together (natriuresis), and tolvaptan raises serum sodium through water removal without increasing sodium excretion, not by increasing sodium excretion.
Option C: Option C is incorrect: furosemide has no V2 receptor-blocking activity and does not affect AQP2 insertion; it acts on NKCC2 in the thick ascending limb, a mechanistically unrelated site.
Option D: Option D is incorrect: furosemide-induced natriuresis removes sodium, which reduces total body sodium and can worsen hyponatremia in patients whose urinary sodium concentration exceeds their plasma sodium; it is not more potent than aquaresis for SIADH correction.
Option E: Option E is incorrect: tolvaptan is specifically contraindicated in hypovolemic hyponatremia caused by total body sodium depletion; aquaresis worsens the underlying sodium deficit by removing free water without replacing lost sodium. Vaptans are indicated for hypervolemic and euvolemic hyponatremia, not hypovolemic hyponatremia.
17. A hospitalized patient with chronic severe hyponatremia (serum sodium 118 mEq/L for at least 48 hours) is started on tolvaptan. Eighteen hours later, repeat labs show serum sodium has risen to 131 mEq/L — a correction of 13 mEq/L. What is the primary danger of this rate of correction, and what is the underlying pathophysiology?
A) Rapid sodium correction causes acute intravascular hypertonicity, driving water from plasma into red blood cells, producing hemolytic anemia and a compensatory thrombocytosis that elevates thromboembolic risk
B) Correction faster than 8–10 mEq/L per 24 hours risks cerebral salt wasting syndrome, in which natriuretic peptide release from the newly hydrated choroid plexus drives further urinary sodium loss and paradoxically worsens hyponatremia
C) Rapid correction of hyponatremia causes acute cerebral hyperemia through loss of the protective blood-brain barrier adaptations that developed during chronic hyponatremia, producing hemorrhagic encephalopathy
D) Correction faster than 8–10 mEq/L in 24 hours (or 18 mEq/L in 48 hours) risks osmotic demyelination syndrome (ODS), in which brain cells adapted to chronic hyponatremia by extruding osmolytes are unable to restore intracellular tonicity rapidly enough when serum sodium rises, causing myelin sheath disruption
E) Too-rapid sodium correction precipitates acute hyperkalemia by driving potassium out of intracellular compartments through the sodium-potassium-ATPase as it responds to the sudden extracellular tonicity change, leading to fatal arrhythmia
ANSWER: D
Rationale:
In chronic hyponatremia, brain cells adapt to the low-osmolality environment by actively extruding organic osmolytes (myoinositol, glutamine, taurine) to reduce intracellular tonicity and prevent cerebral edema. This adaptation takes days to develop. If serum sodium is corrected too rapidly — greater than 8–10 mEq/L in 24 hours or 18 mEq/L in 48 hours — the extracellular osmolality rises faster than brain cells can restore their intracellular osmolyte content. The resulting osmotic stress damages oligodendrocytes and disrupts myelin sheaths, causing osmotic demyelination syndrome (ODS), which classically affects the pons (central pontine myelinolysis) and extrapontine structures. Clinical manifestations include dysarthria, dysphagia, spastic paraparesis, behavioral changes, and in severe cases locked-in syndrome. ODS is largely irreversible. In this patient, a 13 mEq/L correction in 18 hours already exceeds the 24-hour limit, requiring immediate intervention — stopping tolvaptan and considering desmopressin to slow further correction.
Option A: Option A is incorrect: rapid sodium correction does not cause hemolytic anemia; the red blood cell tonicity concern in hyponatremia management relates to central nervous system myelin, not erythrocyte membrane integrity.
Option B: Option B is incorrect: cerebral salt wasting (CSW) is a distinct syndrome of renal sodium loss with true volume depletion, unrelated to the rate of hyponatremia correction; it does not arise from choroid plexus natriuretic peptide release during treatment.
Option C: Option C is incorrect: hemorrhagic encephalopathy from cerebral hyperemia is not the established pathophysiological mechanism of overly rapid hyponatremia correction; ODS is a demyelinating injury, not a hemorrhagic one.
Option E: Option E is incorrect: rapid sodium correction does not cause acute hyperkalemia through Na/K-ATPase-mediated potassium efflux; potassium handling in this context is not the clinically dangerous consequence of too-rapid serum sodium correction.
18. A 34-year-old woman with rapidly progressive autosomal dominant polycystic kidney disease (ADPKD) is being considered for tolvaptan therapy to slow kidney cyst growth. Which safety concern is most critical to address before initiating long-term tolvaptan in this indication?
A) Tolvaptan carries an FDA boxed warning for serious and potentially fatal hepatotoxicity; liver function tests (LFTs) must be checked before initiation and monitored during treatment, and use is restricted to patients with rapidly progressive ADPKD given the chronic exposure duration required
B) Tolvaptan is contraindicated in premenopausal women with ADPKD because V2 receptor blockade in the uterine epithelium impairs implantation, and the drug's long half-life makes it incompatible with pregnancy planning during the treatment period
C) Tolvaptan causes irreversible nephron loss in polycystic kidneys by blocking the V2-mediated cAMP signaling that suppresses cyst epithelial proliferation, accelerating rather than slowing cyst growth in patients with ADPKD PKD2 genotype
D) Tolvaptan is associated with a high rate of sudden cardiac death due to QTc prolongation from V2 receptor blockade in cardiac conducting tissue, requiring a baseline ECG (electrocardiogram) and monthly QTc monitoring throughout therapy
E) Tolvaptan causes severe hyponatremia in ADPKD patients through a paradoxical SIADH-like syndrome triggered by V2 receptor blockade in the hypothalamus, reducing vasopressin clearance and increasing circulating ADH levels above pretreatment baseline
ANSWER: A
Rationale:
Tolvaptan carries an FDA-mandated boxed warning for serious hepatotoxicity, including cases of acute liver failure requiring transplantation and deaths, documented specifically in the ADPKD indication where patients take tolvaptan for years rather than the days or weeks typical of acute hyponatremia management. The risk-benefit calculus for the hyponatremia indication (short-term inpatient use) differs substantially from the ADPKD indication (chronic outpatient use), which is why tolvaptan in ADPKD is restricted to patients with rapidly progressive disease (Mayo classification risk class 1C, 1D, or 1E). The TEMPO 3:4 trial established tolvaptan's efficacy in slowing total kidney volume increase and reducing eGFR decline, but the hepatotoxicity signal emerged from the extended ADPKD studies. LFT monitoring before initiation, after one month, and periodically thereafter is mandated.
Option B: Option B is incorrect: V2 receptors are present in renal collecting duct cells, not uterine epithelium in a meaningful pharmacological sense, and tolvaptan's prescribing restriction in ADPKD is based on hepatotoxicity risk, not reproductive concerns about uterine implantation.
Option C: Option C is incorrect: tolvaptan's mechanism in ADPKD involves blocking V2-driven cAMP accumulation in cyst epithelial cells, which reduces cyst cell proliferation and fluid secretion — this is the established therapeutic basis, not a source of cyst acceleration. PKD2 genotype is associated with slower disease progression, not a reversal of tolvaptan's mechanism.
Option D: Option D is incorrect: tolvaptan is not associated with QTc prolongation or sudden cardiac death; V2 receptors are not expressed in cardiac conducting tissue in a way that generates arrhythmia risk.
Option E: Option E is incorrect: tolvaptan does not cause hyponatremia; it raises serum sodium by promoting free water excretion. V2 receptor blockade at the hypothalamic level is not a pharmacological concern with tolvaptan.
19. Conivaptan differs from tolvaptan in several pharmacologically important ways. Which of the following correctly characterizes conivaptan and explains its restriction to inpatient IV use?
A) Conivaptan is a highly selective V2 receptor antagonist with greater aquaretic potency than tolvaptan, but its narrow therapeutic index requires continuous IV infusion in monitored settings to prevent excessively rapid sodium correction
B) Conivaptan selectively blocks V1b receptors in the anterior pituitary, reducing ACTH secretion and causing clinically significant adrenal suppression that requires inpatient monitoring and steroid supplementation
C) Conivaptan blocks both V1a and V2 receptors and is available only as an IV formulation; V1a blockade produces vasodilation that limits use in hypotensive patients, and conivaptan is a potent CYP3A4 inhibitor with a significant drug interaction burden that contributed to its restriction to the inpatient IV setting
D) Conivaptan is available in both IV and oral formulations but carries a higher hepatotoxicity risk than tolvaptan due to biliary concentration; the inpatient-only restriction applies to the IV formulation pending long-term hepatic safety data for the oral form
E) Conivaptan is preferred over tolvaptan in hypovolemic hyponatremia because its V1a blockade promotes vasopressin-independent renal sodium retention, compensating for the sodium depletion that characterizes this condition while simultaneously generating aquaresis
ANSWER: C
Rationale:
Conivaptan is a non-selective vasopressin antagonist that blocks both V1a receptors (expressed on vascular smooth muscle, where vasopressin promotes vasoconstriction) and V2 receptors (expressed in renal collecting duct principal cells, where vasopressin drives AQP2 insertion). The V1a blockade produces vasodilation, limiting conivaptan's use in hemodynamically unstable or hypotensive patients — a constraint that does not apply to the V2-selective tolvaptan. Conivaptan is additionally a potent inhibitor of cytochrome P450 3A4 (CYP3A4), creating significant drug interaction potential with the many common medications metabolized by this pathway. The combination of V1a-mediated hemodynamic instability risk, the CYP3A4 drug interaction burden, and the need for close osmolality and sodium monitoring confined its approval to an IV inpatient formulation. It is approved for euvolemic or hypervolemic hyponatremia in hospitalized patients.
Option A: Option A is incorrect: conivaptan is not a selective V2 antagonist; its defining pharmacological feature is non-selectivity, blocking both V1a and V2 receptors. Inpatient restriction is due to multiple factors including V1a-mediated vasodilation and CYP3A4 inhibition, not solely narrow therapeutic index.
Option B: Option B is incorrect: V1b receptors are expressed in the anterior pituitary and mediate ACTH release, but conivaptan does not selectively block V1b; it blocks V1a and V2, and adrenal suppression is not a recognized clinical concern with conivaptan use.
Option D: Option D is incorrect: conivaptan has no approved oral formulation; it is available exclusively as an IV product.
Option E: Option E is incorrect: conivaptan is contraindicated in hypovolemic hyponatremia, as is tolvaptan; neither vaptan is appropriate when hyponatremia results from total body sodium depletion, and V1a blockade does not promote renal sodium retention — it causes vasodilation.
20. A patient with refractory heart failure has been on furosemide 80 mg twice daily for six months with initially good diuresis, but natriuretic response has now diminished despite adequate drug levels and compliance. Which mechanism best explains the development of loop diuretic resistance in this patient?
A) Furosemide undergoes accelerated hepatic CYP3A4 metabolism after months of exposure, inducing its own clearance and reducing plasma concentrations below the threshold needed to block NKCC2 in the thick ascending limb
B) Chronic furosemide use causes downregulation of NKCC2 expression in the thick ascending limb by a feedback mechanism that responds to persistent NKCC2 blockade, permanently reducing the number of available transporter targets
C) Furosemide binds irreversibly to NKCC2 after six months of continuous use, and the pool of reversibly-blockable transporters is progressively exhausted, reducing the pharmacologically accessible target population
D) Chronic furosemide exposure reduces aldosterone secretion through volume contraction, and the resulting low aldosterone state reduces ENaC expression in the collecting duct, paradoxically increasing sodium reabsorption by eliminating aldosterone's normal inhibitory tone on ENaC
E) With chronic loop diuretic use, the distal convoluted tubule (DCT) and collecting duct (CD) undergo hypertrophy and upregulate the Na-Cl cotransporter (NCC), ENaC, and Na/K-ATPase in response to chronically elevated sodium delivery, allowing greater downstream sodium reabsorption that partially negates the loop diuretic's natriuretic effect
ANSWER: E
Rationale:
Sequential nephron blockade addresses the fundamental mechanism of loop diuretic resistance: distal tubular adaptation. When loop diuretics chronically deliver elevated sodium loads to the distal convoluted tubule and collecting duct, these segments respond with structural hypertrophy and upregulation of the sodium transport machinery — NCC (Na-Cl cotransporter, the target of thiazides), ENaC (epithelial sodium channel, the target of potassium-sparing diuretics), and basolateral Na/K-ATPase. Over time, the increased capacity of the DCT and CD to reabsorb sodium partially offsets the NKCC2 blockade achieved by furosemide, reducing the net natriuretic response. Adding a thiazide (especially metolazone) blocks NCC simultaneously, preventing this compensatory reabsorption and restoring effective diuresis.
Option A: Option A is incorrect: furosemide does not induce its own CYP3A4 metabolism significantly over time; auto-induction of clearance is not a recognized mechanism of loop diuretic resistance. Furosemide is eliminated primarily renally unchanged, not through hepatic CYP3A4 catabolism.
Option B: Option B is incorrect: NKCC2 does not undergo downregulation in response to chronic blockade; in fact, NKCC2 may be upregulated in some settings, and the resistance is a downstream DCT/CD hypertrophy phenomenon, not a target loss at the loop.
Option C: Option C is incorrect: furosemide binds NKCC2 reversibly and competitively; irreversible binding and transporter pool exhaustion are not mechanisms of furosemide pharmacology.
Option D: Option D is incorrect: chronic furosemide use activates secondary hyperaldosteronism (not suppresses aldosterone) through the volume contraction it produces; this elevated aldosterone actually upregulates ENaC and Na/K-ATPase in the collecting duct, contributing to diuretic resistance rather than causing it through low-aldosterone ENaC suppression.
21. When adding metolazone to a loop diuretic for sequential nephron blockade in a patient with refractory volume overload and an eGFR of 22 mL/min/1.73 m², which of the following reflects correct prescribing practice and explains metolazone's advantage over hydrochlorothiazide (HCTZ) in this setting?
A) Metolazone should be given 30–60 minutes after the loop diuretic dose so that the NKCC2-driven increase in DCT sodium delivery is already established before NCC blockade begins, synchronizing the two mechanisms at peak tubular sodium concentrations
B) Metolazone should be given 30–60 minutes before the loop diuretic dose so that NCC blockade in the DCT is established before the loop-diuretic-driven sodium bolus arrives; metolazone also retains efficacy when eGFR falls below 30 mL/min/1.73 m², unlike HCTZ, which loses meaningful NCC-blocking activity at low GFR
C) Metolazone and HCTZ are pharmacodynamically interchangeable in patients with eGFR below 30 mL/min/1.73 m²; metolazone is preferred solely because of its lower cost and greater availability as a generic formulation in the inpatient setting
D) Metolazone should be dosed simultaneously with the loop diuretic because pharmacokinetic modeling shows that peak plasma concentrations of both agents must coincide to produce additive NKCC2 and NCC blockade within the same tubular fluid transit time
E) Metolazone is dosed after the loop diuretic response is assessed (6–8 hours post-furosemide) to allow titration of the sequential blockade dose based on observed urine output, reducing the risk of precipitous volume depletion from premature NCC blockade
ANSWER: B
Rationale:
The clinical rationale for pre-dosing metolazone 30–60 minutes before the loop diuretic is mechanistic: the loop diuretic blocks NKCC2 in the thick ascending limb, generating a large sodium bolus that is delivered downstream to the DCT. If metolazone's NCC blockade is not yet established when this sodium arrives, the DCT can reabsorb it through its upregulated NCC transporters, negating much of the loop-induced natriuresis. By pre-dosing metolazone, NCC is already blocked when the sodium load arrives, preventing this compensatory reabsorption. Metolazone's advantage over hydrochlorothiazide (HCTZ) in this patient (eGFR 22 mL/min/1.73 m²) is its retained efficacy at low GFR: HCTZ loses meaningful NCC-blocking activity when GFR falls below 30 mL/min/1.73 m² because it relies on tubular secretion into the lumen to reach its transporter target — a process impaired in CKD. Metolazone reaches the tubular lumen through different mechanisms and maintains efficacy even at low GFR. The combination carries significant risk of hypokalemia, volume depletion, and AKI, requiring close electrolyte and renal function monitoring within 24–48 hours.
Option A: Option A is incorrect: the timing is reversed — metolazone must precede (not follow) the loop diuretic so that NCC blockade is established before the loop-driven sodium delivery. Post-dosing would allow the DCT to absorb the sodium bolus before NCC is blocked.
Option C: Option C is incorrect: metolazone and HCTZ are not pharmacodynamically interchangeable at low GFR; HCTZ loses efficacy at eGFR below 30 mL/min/1.73 m², which is precisely this patient's clinical situation.
Option D: Option D is incorrect: simultaneous dosing does not allow time for metolazone to establish NCC blockade before the loop diuretic-driven sodium arrives at the DCT; peak plasma concentration synchronization is not the pharmacologically relevant goal.
Option E: Option E is incorrect: a 6–8 hour post-furosemide assessment window for metolazone dosing would miss the DCT sodium delivery window entirely and would not produce the intended sequential blockade effect.
22. The ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial demonstrated benefit from adding acetazolamide to IV loop diuretics in hospitalized patients with decompensated heart failure. Which of the following best explains the physiological rationale for this combination and the trial's primary finding?
A) Acetazolamide enhances furosemide's delivery to the thick ascending limb by inhibiting proximal tubular organic anion transporter (OAT) competition, increasing furosemide luminal concentration and restoring NKCC2 blockade efficiency in loop diuretic-resistant patients
B) Acetazolamide reduces vasopressin secretion by correcting the hyponatremia that triggers ADH release in decompensated heart failure, reducing AQP2-mediated water retention in the collecting duct and complementing loop diuretic-driven natriuresis
C) Acetazolamide inhibits cardiac carbonic anhydrase isoforms, directly reducing myocardial oxygen consumption and improving cardiac output in decompensated heart failure, which secondarily enhances renal perfusion and potentiates furosemide response
D) Metabolic alkalosis from chronic loop diuretic use reduces loop diuretic responsiveness by upregulating proximal NHE3 activity through angiotensin II stimulation; acetazolamide corrects this alkalosis via bicarbonaturia, restoring the tubular pH milieu that favors diuretic efficacy, and provides additional natriuresis — the ADVOR trial demonstrated improved successful decongestion at three days with this combination versus loop diuretic alone
E) Acetazolamide prevents the rebound sodium retention that occurs in the 12-hour interdose interval between furosemide doses by providing continuous carbonic anhydrase inhibition in the proximal tubule, eliminating the natriuretic fluctuation that underlies loop diuretic resistance in heart failure
ANSWER: D
Rationale:
Loop and thiazide diuretics generate metabolic alkalosis through volume contraction, hypokalemia, and secondary hyperaldosteronism. In decompensated heart failure, metabolic alkalosis reduces loop diuretic responsiveness through a specific mechanism: elevated bicarbonate and the associated angiotensin II-driven upregulation of proximal NHE3 increases sodium-hydrogen exchange in the PCT, enhancing sodium and chloride reabsorption before the drug can act at the loop. When less sodium and fluid reach the loop of Henle, the natriuretic effect of NKCC2 blockade is diminished. Acetazolamide corrects this alkalosis by forcing bicarbonaturia — restoring the tubular pH milieu that allows normal loop diuretic delivery to the loop of Henle — and simultaneously provides additional natriuresis through bicarbonate wasting in its own right. The ADVOR trial (published in NEJM 2022) demonstrated that acetazolamide added to standardized IV loop diuretic therapy increased the rate of successful decongestion at three days compared with placebo in hospitalized decompensated heart failure patients, providing trial-level evidence for this combination strategy.
Option A: Option A is incorrect: acetazolamide does not inhibit organic anion transporters (OAT) and does not enhance furosemide's luminal delivery; this is a mechanistically fabricated distractor. Furosemide's delivery to its tubular site is not the primary mechanism of loop diuretic resistance addressed by the ADVOR combination.
Option B: Option B is incorrect: acetazolamide does not reduce vasopressin secretion; its mechanism is renal carbonic anhydrase inhibition producing bicarbonaturia. Hyponatremia-related vasopressin regulation is separate from acetazolamide's mode of action.
Option C: Option C is incorrect: acetazolamide does not have a clinically relevant direct cardiac effect on myocardial oxygen consumption; its benefit in decompensated heart failure is entirely through renal tubular mechanisms.
Option E: Option E is incorrect: while rebound sodium retention in diuretic interdose intervals is a real phenomenon contributing to loop diuretic resistance, it is addressed by dosing frequency adjustments or continuous infusion, not acetazolamide; acetazolamide's role is metabolic alkalosis correction and proximal bicarbonaturia, not interdose interval management.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.